Key takeaways
Although side effects can occur, Ozempic has a good safety profile. Serious adverse events are less common.
Ozempic is a GLP-1 receptor agonist medication that’s FDA-approved to treat type 2 diabetes. It’s also used off-label for weight loss and is generally safe to use for this purpose in most people who qualify for treatment.
Ozempic mimics a natural hormone in your body and works by improving blood sugar control and reducing hunger.
The most common side effects are nausea, vomiting, diarrhea, abdominal pain, and constipation. Your healthcare provider can give you tips to help manage side effects.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Although side effects can occur, Ozempic has a good safety profile. Serious adverse events are less common.
Ozempic is a GLP-1 receptor agonist medication that’s FDA-approved to treat type 2 diabetes. It’s also used off-label for weight loss and is generally safe to use for this purpose in most people who qualify for treatment.
Ozempic mimics a natural hormone in your body and works by improving blood sugar control and reducing hunger.
The most common side effects are nausea, vomiting, diarrhea, abdominal pain, and constipation. Your healthcare provider can give you tips to help manage side effects.
Ozempic (semaglutide) is a GLP-1 medication, available as both a pill and injection. It’s approved for people with type 2 diabetes, but is Ozempic safe for weight loss?
It can be prescribed off-label for this purpose, and is generally considered safe, as long as you’re cleared to take it by a healthcare provider and you take it as directed. However, like any medication, it does come along with a risk of side effects. Read on to learn more.
Is Ozempic safe?
Yes, Ozempic is generally safe, as long as your healthcare provider determines it’s a good fit for you (and as long as you take it the way you’re supposed to).
Both the Ozempic pill and injection are approved by the US Food and Drug Administration (FDA) for people with type 2 diabetes. By definition, FDA approval means they’ve undergone extensive clinical trials to show they are safe and effective.
However, as with any other medication, side effects can occur, and there are some rarer serious side effects and risks — more on that later.
How does it work?
Ozempic is in a class of medications called glucagon-like peptide-1 receptor agonists (GLP-1). GLP-1 medications work by mimicking the GLP-1 incretin hormone that the body naturally produces. Incretin hormones are peptides the intestine releases into the bloodstream when we eat.
GLP-1 has several functions, including:
Helping with glucose (blood sugar) regulation by increasing insulin release when glucose is elevated
Altering the hunger and fullness signals the brain receives
Slowing the rate of food moving from the stomach to the small intestine
How does Ozempic work for type 2 diabetes?
If you have type 2 diabetes, your body may secrete less GLP-1 hormone. Ozempic acts like GLP-1, producing some of the benefits of this hormone, including better blood sugar control.
When you eat, glucose rises in the bloodstream. Your pancreas produces and releases the hormone insulin in response to a rise in glucose, since insulin aids in transporting glucose into cells to be used for energy.
People with type 2 diabetes have insulin resistance, meaning their cells no longer respond as well to insulin. Therefore, blood sugar levels stay high. Beta cells in the pancreas respond by producing even more insulin, but eventually, they can’t produce enough to keep up with the high glucose levels. As a result, blood sugar continues to increase.
The GLP-1 hormone stimulates your pancreas to release more insulin when blood sugar is elevated. By mimicking this hormone, Ozempic functions in a similar fashion. The increased insulin production can help lower high blood sugar, aiding in the treatment of type 2 diabetes.
In clinical trials, the Ozempic injection lowered A1C by 1.4%--1.6% over 30 weeks, and the Ozempic pill lowered A1C by 1.2%--1.4% over 26 weeks.
How does Ozempic work for weight loss?
People who have obesity or overweight may also experience reduced GLP-1 secretion. The GLP-1 hormone that Ozempic mimics helps to slow gastric emptying (the rate at which food moves out of your stomach and into the lower intestine). Slower gastric emptying can make you feel fuller faster and satisfied for longer after meals.
Ozempic also activates the GLP-1 receptors in the brain, resulting in the activation of certain neurons and the inactivation of others. Through these processes, Ozempic helps regulate appetite and quiet “food noise.” Food noise is a collective term to describe having persistent and intrusive thoughts about food.
“We have GLP receptors throughout our body, including in our gastrointestinal system (stomach, liver, and pancreas), as well as in the brain,” says Sarah Stombaugh, MD, a family medicine physician and diplomat of the American Board of Obesity Medicine.
“Stimulating GLP has multiple effects which impact weight, including decreased insulin resistance, slower gastrointestinal transit time, and decreased hunger and cravings.”
By reducing appetite and silencing food noise, Ozempic can help you eat less, feel more satisfied at meals, and feel satisfied with smaller amounts of food.
Is Ozempic effective for weight loss?
While Ozempic is indicated for type 2 diabetes, research on semaglutide has shown that it can lead to significant weight loss.
“Medications like Ozempic can be a helpful tool when used as part of a comprehensive approach that includes lifestyle modifications,” says Resham Uttamchandani, MD, founder of Doctor U, who is double-board certified in family medicine and obesity medicine. “The most effective strategy is personalized and may evolve over time.”
Semaglutide weight loss results
Below are examples of weight loss results from studies looking at injectable and oral semaglutide.
In one 30-week-long clinical trial, people with type 2 diabetes taking 0.5 mg of injectable semaglutide lost about 8 pounds, and those taking 1.0 mg lost about 10 pounds by the end of the study.
In a 40-week-long study, people with type 2 diabetes taking 1.0 mg of injectable semaglutide lost ~12–13 pounds by the end of the study.
In a 26-week-long study, people with type 2 diabetes taking oral semaglutide lost an average of about 6 lbs after 3 months and nearly 9 pounds after 6 months.
Ozempic and other oral and injectable GLP-1 medications are designed to be used in combination with diet and exercise to see more significant and sustainable results.
“If someone has struggled with health consequences of their weight and has found diet and exercise alone have not been enough to support their weight goals, medications like semaglutide may be a good option to support their health and weight goals,” Dr. Stombaugh says.
Long-term use and rebound weight gain
To see sustained weight loss results, you have to take Ozempic for a long time. Your healthcare provider can offer guidance on how long you’ll need to take Ozempic, factoring in things like your weight loss goals, your overall health, and how well you tolerate any side effects.
Research shows that stopping semaglutide may lead to regaining the weight you lost while taking the medication.
Studies haven’t looked at rebound weight gain for the maximum dose of Ozempic. However, in one randomized controlled trial of 2.4 mg of injectable semaglutide, participants regained about two-thirds of the weight they lost after discontinuing semaglutide and stopping lifestyle changes for a full year. This rebound weight gain occurred after participants had been on the medication for a little over a year, and had made lifestyle changes, including diet and exercise, during that time.
Currently, we don’t have similar data looking at rebound weight gain long-term after discontinuing oral semaglutide.
If you are interested in taking Ozempic for weight loss, long-term treatment may be needed to sustain the weight management benefits of the medication.
Lifestyle changes and Ozempic
Taken as a whole, research results for semaglutide illustrate the need for making certain lifestyle changes while taking Ozempic — and maintaining them even after stopping the medication.
“Patients who combine GLP-1 medications like semaglutide with intensive lifestyle modification including nutrition, movement, sleep, and stress management have better long-term weight loss compared to patients who use GLP-1 medications or lifestyle modification alone,” Dr. Stombaugh says.
When considering changes to physical activity, weight training may be especially important if you use Ozempic. This is because research shows that some of the weight lost with semaglutide can come from lean mass as well as fat. Muscle loss over time can have negative effects on overall health. But you can maintain muscle mass through resistance exercise and other strategies.
The bottom line: Consult with a knowledgeable healthcare provider before using Ozempic. They can help you decide if the medication is right for you and can provide useful tips and guidance for sustainable approaches to weight loss and blood sugar control.
Ozempic side effects for weight loss and type 2 diabetes
As with any medication, Ozempic does have some potential side effects. The side effects are generally the same whether you take Ozempic for type 2 diabetes or weight loss. Additionally, the side effects are largely the same whether you’re taking the Ozempic tablet or injection, since the active ingredient is the same.
“While generally well-tolerated, Ozempic can cause mostly gastrointestinal side effects,” Dr. Uttamchandani adds.

Common side effects
The most common reported side effects for both injectable and oral Ozempic include:
Abdominal pain
Constipation
Diarrhea
Nausea
Vomiting
Tips for managing common side effects of Ozempic
Common GI side effects tend to be mild and go away as your body adjusts to the medication. But that doesn’t mean you have to power through discomfort while taking Ozempic. Talk to your provider about ways to manage and minimize common side effects.
The following strategies may help you manage or reduce common side effects:
Start at the lowest dose and slowly increase it over time. Side effects tend to be most intense when first starting Ozempic or when moving up to the next dose strength.
Don’t skip doses. Starting at higher doses or jumping dose strengths increases your risk for more severe side effects.
Drink plenty of water. Some common side effects can lead to dehydration, so make sure you’re taking in plenty of fluids each day.
Eat smaller, more frequent meals. This may help to curb nausea and other GI discomfort as your body adjusts to the medication.
Ask your healthcare provider about anti-nausea meds. Your provider may recommend a prescription or over-the-counter medication to help with nausea and vomiting.
Warnings and precautions for Ozempic
Serious adverse events may also occur with Ozempic, though these are uncommon.
“Semaglutide is a safe medication when used under the supervision of a provider who is experienced with GLP-1 medications,” Dr. Stombaugh says. “While mild side effects, such as nausea and constipation, are common from this medication, serious side effects, like bowel obstruction or gastroparesis, are rare and may be avoidable with close monitoring.”
Contact your healthcare provider immediately if you experience any of the following. Some symptoms, such as a severe allergic reaction, require emergency care.
Allergic reactions. Symptoms may include facial or throat swelling, difficulty breathing or swallowing, itching or rash, fainting or feeling dizzy, or rapid heartbeat.
Inflammation of your pancreas (pancreatitis). Symptoms may include severe abdominal pain that doesn’t go away and sometimes back pain.
Gallbladder problems. Symptoms may include pain in your upper abdomen, fever, yellowing of the skin or eyes, or clay-colored stools.
Acute kidney injury. Persistent vomiting or diarrhea can cause dehydration, which can sometimes lead to kidney injury, including in people without pre-existing kidney disease.
Low blood sugar (hypoglycemia). Symptoms may include dizziness or lightheadedness, blurred vision, mood changes, sweating, slurred speech, hunger, confusion, drowsiness, shakiness, weakness, headache, rapid heartbeat, or feeling jittery. The risk is especially increased when Ozempic is used with insulin or a sulfonylurea.
Vision changes. Symptoms may include blurred vision, floaters, or spots. For people with type 2 diabetes who also have a history of diabetic retinopathy (a condition that can cause blood vessel damage in the retina), Ozempic may worsen symptoms. If you have a known history of diabetic retinopathy, you should be closely monitored.
Gastroparesis or bowel obstruction. Some research has found that semaglutide is associated with gastroparesis (stomach paralysis) and bowel obstruction.
“There is a boxed warning for the potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), and this needs to be screened for before initiating any medications,” Dr. Uttamchandani says.
Tell your healthcare provider if you experience a lump or swelling in your neck, trouble swallowing, shortness of breath, or hoarseness, as these may be signs of a thyroid tumor. Ozempic and other GLP-1s should not be used in people with a personal or family history of MTC or MEN 2 syndrome.
Drug interactions for Ozempic
Here are some considerations and potential drug interactions for Ozempic. Some apply to both injectable Ozempic and oral Ozempic, while others depend on which formulation you take
Oral medications. If you take medications by mouth, Ozempic can potentially affect how well you absorb them. This is because Ozempic can delay gastric emptying. However, with injectable Ozempic, studies did not find clinically meaningful changes in absorption of oral medications. Oral Ozempic has additional considerations because it must be taken on an empty stomach and can affect exposure to certain medications, such as levothyroxine.
Insulin and sulfonylureas. You may also be at a higher risk of experiencing low blood sugar while taking Ozempic if you take insulin or a sulfonylurea (a class of diabetes medications that stimulates insulin secretion).
GLP-1s. Ozempic should not be taken with other GLP-1 medications, as this could lead to more severe side effects.
Ozempic may interact with other medications, so it’s important to tell your healthcare provider about all the prescription or over-the-counter medications, supplements, and herbs you’re taking.
Who should not use Ozempic?
Ozempic isn’t right for everyone. Some people should not use it at all, while others need special guidance from their healthcare provider. Do not use Ozempic if:
You’re allergic to any ingredients in the medication.
You or a family member have ever had medullary thyroid carcinoma (a specific type of thyroid cancer) or multiple endocrine neoplasia type 2 (aka MEN 2, a condition that affects the endocrine system).
Talk to your healthcare provider before taking Ozempic if:
If you have a personal or family history of kidney problems, pancreatitis, or diabetic retinopathy
You are pregnant, breastfeeding, or planning to become pregnant.
Additionally, if you have a surgery planned, consult your healthcare provider, since taking Ozempic before surgery could lead to complications. Ozempic may cause an increased risk of liquid or food getting into your lungs while you’re under anesthesia or deeply sedated. They may recommend stopping the medication for a certain amount of time before surgery.
Ozempic vs. Wegovy and other injectable GLP-1s
Ozempic and Wegovy are two brand names for the injectable or oral medication semaglutide. While both medications are FDA-approved, they have different indications and come in different doses. Both Ozempic and Wegovy are generally considered safe, as long as a healthcare provider determines that semaglutide is the right fit for you.
When medications are FDA-approved, they’ve undergone extensive clinical trials to ensure safety. Other FDA-approved, injectable medications in this class that are indicated to treat type 2 diabetes or obesity include liraglutide (Saxenda)and tirzepatide (Zepbound, Mounjaro), a GIP/GLP-1 receptor agonist.
According to a 2025 systematic review of obesity trials, there were more adverse events with liraglutide 3 mg than with semaglutide 2.4 mg or tirzepatide 10–15 mg. In that analysis, tirzepatide had a higher risk of clinically significant hypoglycemia below.
Always talk to an experienced and knowledgeable healthcare provider before trying a new medication. Your provider can help determine whether you’re a good candidate for a GLP-1 like Ozempic and provide more information on the potential benefits and risks. They’ll consider your health goals, personal and family health history, current health status, any medications or supplements you’re taking, and other health-related factors to determine if GLP-1 medications are a safe and appropriate option for you.
Bottom line
Ozempic is a GLP-1 medication used to treat type 2 diabetes and may be used off-label for weight loss. It works by helping with blood sugar management and reducing hunger.
Ozempic has been studied for safety and efficacy and is generally considered safe.
Common GI side effects like nausea, diarrhea, and abdominal pain tend to be mild and manageable. More serious adverse effects are rare.
Working with a knowledgeable healthcare provider can help you manage mild side effects and minimize your risk for any health complications.
Some people should not take Ozempic due to a higher risk of adverse effects or drug interactions. Always talk to a knowledgeable healthcare provider before taking a new medication.
Frequently asked questions (FAQ)
Is Ozempic safe for weight loss?
Whether Ozempic is safe for you depends on your medical history, other medications, and individual risk factors. Ozempic isn't FDA-approved specifically for weight management, but clinicians sometimes prescribe it off-label for that purpose. Semaglutide has been extensively studied in people with overweight or obesity and has a well-characterized safety profile.
As with any medication, Ozempic may cause side effects, though these are generally mild and manageable and include GI issues like nausea, diarrhea, and constipation.
Ozempic may not be the best option for everyone. People with a personal or family history of certain thyroid tumors, pancreatitis, or kidney problems may be at higher risk for health complications with Ozempic. Working with an experienced clinician can help you determine if Ozempic is safe for you.
Are there long-term safety risks with Ozempic?
Ozempic and other injectable GLP-1 medications are meant to be taken long term to sustain weight loss and blood sugar control, and have a good safety profile.
Semaglutide now has randomized clinical-trial safety data extending to roughly four years. These long-term studies have not identified an overall increase in serious adverse events compared with placebo, although gastrointestinal side effects and stopping treatment because of side effects can be more common with semaglutide.
That said, some people should not take Ozempic, while others may need additional monitoring based on their medical history. For example, Ozempic is contraindicated in people with a personal or family history of MTC or MEN 2, and conditions such as a history of pancreatitis, diabetic retinopathy, severe gastroparesis, or kidney disease should be discussed with your healthcare provider.
What are the benefits of taking Ozempic?
Ozempic has benefits for blood sugar management, which can help with type 2 diabetes. It also helps regulate appetite, which can make it easier to lose weight.
Beyond this, injectable Ozempic can reduce the risk of major adverse cardiovascular events in adults who have type 2 diabetes and established cardiovascular disease. Ozempic tablets can reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for cardiovascular events.
Injectable Ozempic can also reduce the risk of eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
What are the cons of taking Ozempic?
As with any medication, Ozempic may cause side effects. While the most common side effects are generally mild and manageable, they can be unpleasant, especially when first starting the medication or just after a dose increase.
Ozempic may lead to weight loss, but some of the weight you lose may be muscle mass. Because lean mass includes muscle, resistance exercise and adequate nutrition can be helpful for supporting muscle mass and physical function during weight loss.
Ozempic is a long-term medication, and most people need to take the drug for at least a year to maintain weight loss results.
Lastly, Ozempic can be expensive, costing around $1,000 per month out-of-pocket. Insurance and savings programs can help reduce the cost of Ozempic, but keep in mind that some insurance plans will not cover medications that are used off-label (such as if your provider prescribes it for weight loss rather than one of the FDA-indicated uses).
What about “Ozempic face?”
“Ozempic face” is a term coined on social media that describes possible changes to a person’s appearance after using a weight loss drug. That might include a loss of volume in the face, a “sunken” look in the cheeks, sagging skin, and signs of premature aging.
While there are anecdotal reports of people’s facial appearance changing after using weight loss medication, it’s unclear if these changes are due to the medications themselves or simply an outcome of significant weight loss. More research is needed to understand if or how medications like semaglutide might impact facial volume.
As always, discuss any questions or concerns you might have about Ozempic with your provider.
What happens if you take Ozempic without diabetes?
Ozempic helps people with type 2 diabetes have better blood sugar control, but semaglutide can also affect appetite, body weight, and glucose metabolism in people who do not have diabetes.
Having better blood sugar control also benefits people with prediabetes or other conditions like insulin resistance or polycystic ovarian syndrome (PCOS) — however, Ozempic is not FDA-approved for these indications. Wegovy is the semaglutide product FDA-approved for chronic weight management.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
Saxenda Important Safety Information: Read more about serious warnings and safety info.
Zepbound Important Safety Information: Read more about serious warnings and safety info.
Mounjaro Important Safety Information: Read more about serious warnings and safety info.
References
Baggio, L. L. & Drucker, D. J. (2014). Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. The Journal of Clinical Investigation, 124(10), 4223. doi: 10.1172/JCI78371. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC4191040/
Collins, L. & Costello, R. A. (2024). Glucagon-like peptide-1 receptor agonists. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK551568/
Crisafulli, S., Alkabbani, W., Paik, J. M., et al. (2026). Comparative gastrointestinal safety of dulaglutide, semaglutide, and tirzepatide in adults with type 2 diabetes. Annals of Internal Medicine, 179(1), 1–11. doi: 10.7326/ANNALS-25-01724. Retrieved from https://www.acpjournals.org/doi/10.7326/ANNALS-25-01724
Freeman, A. M., Acevedo, L. A., & Pennings, N. (2023). Insulin resistance. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK507839/
Frías, J. P., Auerbach, P., Bajaj, H. S., et al. (2021). Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The Lancet. Diabetes & Endocrinology, 9(9), 563–574. doi: 10.1016/S2213-8587(21)00174-1. Retrieved from https://pubmed.ncbi.nlm.nih.gov/34293304/
Garvey, W. T., Batterham, R. L., Bhatta, M.,et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. doi: 10.1038/s41591-022-02026-4. Retrieved from https://www.nature.com/articles/s41591-022-02026-4
Hayashi, D., Edwards, C., Emond, J. A., et al. (2023). What is food noise? A conceptual model of food cue reactivity. Nutrients, 15(22), 4809. doi: 10.3390/nu15224809. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10674813/
Ida, S., Kaneko, R., Imataka, K., et al. (2021). Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Current Diabetes Reviews, 17(3), 293-303. doi: 10.2174/1573399816666200705210006. Retrieved from https://pubmed.ncbi.nlm.nih.gov/32628589/
Jensterle, M., Ferjan, S., Ležaič, L., et al. (2023). Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity, and Metabolism, 25(4), 975-984. doi: 10.1111/dom.14944. Retrieved from https://pubmed.ncbi.nlm.nih.gov/36511825/
Kamel-El Sayed, S. A. & Mukherjee, S. (2023). Physiology, pancreas. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK459261/
Knudsen, L. B. & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology (Lausanne), 10, 155. doi: 10.3389/fendo.2019.00155. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31031702/
Kommu, S. & Whitfield, P. (2024). Semaglutide. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK603723/
Kushner, R. F., Ryan, D. H., Deanfield, J., et al. (2025). Safety profile of semaglutide versus placebo in the SELECT study: A randomized controlled trial. Obesity, 33(3), 452–462. doi: 10.1002/oby.24222. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39948761/
Liu, L., Chen, J., Wang, L.,et al. (2022) Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Frontiers of Endocrinology, 13, 1043789. doi: 10.3389/fendo.2022.1043789. Retrieved from https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1043789/full
Liu, J., Yang, X., Yu, S., & Zheng, R. (2018). The leptin resistance. Advances in Experimental Medicine and Biology, 1090, 145-163. doi: 10.1007/978-981-13-1286-1_8. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30390289/
Montecinos, K., Kania, B., & Goldberg, D. J. (2024). Semaglutide “Ozempic” face and implications in cosmetic dermatology. Dermatological Reviews, 5(5), e70003. doi: 10.1002/der2.70003. Retrieved from https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70003
McGuire, D. K., Marx, N., Mulvagh, S. L., et al. (2025). Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. The New England Journal of Medicine, 392(20), 2001–2012. doi: 10.1056/NEJMoa2501006. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2501006
Müller, T. D., Finan, B., Bloom, S. R., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. doi: 10.1016/j.molmet.2019.09.010. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31767182/
NovoCare. (2026). Find out the cost for Ozempic. Novo Nordisk. Retrieved from https://www.novocare.com/ozempic/let-us-help/explaining-list-price.html
Popoviciu, M. S., Păduraru, L., Yahya, G., et al. (2023). Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. International Journal of Molecular Sciences, 24(13), 10449. doi: 10.3390/ijms241310449. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10341852/
Ryan, D. H., Lingvay, I., Deanfield, J., et al. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine, 30(7), 2049-2057. doi: 10.1038/s41591-024-02996-7. Retrieved from https://www.nature.com/articles/s41591-024-02996-7
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., et al. (2023). Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA, 330(18), 1795. doi: 10.1001/jama.2023.19574. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10557026/
U.S. Food and Drug Administration (FDA). (2026-a). Highlights of Prescribing Information: Mounjaro (tirzepatide) injection, for subcutaneous use. Retrieved from fhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf
U.S. Food and Drug Administration (FDA). (2026-b). Highlights of Prescribing Information: Ozempic (semaglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf
U.S. Food and Drug Administration (FDA). (2026-c). Highlights of Prescribing Information: Rybelsus (semaglutide) tablets, for oral use. Ozempic (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051Orig1s030lbl.pdf
U.S. Food and Drug Administration (FDA). (2026-d). Highlights of Prescribing Information: Saxenda (liraglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321Orig1s024lbl.pdf
U.S. Food and Drug Administration (FDA). (2026-e). Highlights of Prescribing Information: Zepbound (tirzepatide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
Volpe, S., Lisco, G., Fanelli, M., et al.(2023). Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study. Frontiers in Endocrinology, 14, 1240263. doi: 10.3389/fendo.2023.1240263. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10534984/
Wadden, T. A., Chao, A. M., Moore, M., et al. (2023). The role of lifestyle modification with second-generation anti-obesity medications: comparisons, questions, and clinical opportunities. Current Obesity Reports, 12(4), 453. doi: 10.1007/s13679-023-00534-z. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10748770/
Wilding, J. P. H, Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. doi: 10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Wilding, J. P. H., Batterham, R. L., Davies, M., et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity & Metabolism, 24(8), 1553–1564. doi: 10.1111/dom.14725. Retrieved from https://pubmed.ncbi.nlm.nih.gov/35441470/
Xie, Z., Liang, Z., Xie, Y., et al. (2025). Comparative safety of GLP-1/GIP co-agonists versus glp-1 receptor agonists for weight loss in patients with obesity or overweight: a systematic review. Diabetes, Metabolic Syndrome, and Obesity, 18, 2837-2849. doi: 10.2147/DMSO.S537229. Retrieved from https://www.dovepress.com/comparative-safety-of-glp-1gip-co-agonists-versus-glp-1-receptor-agoni-peer-reviewed-fulltext-article-DMSO















